Influenza A virus H5N1 hemagglutinin and neuraminidase (H5N1 HA/NA)

Influenza A H5N1 viral hemagglutinin (HA) and neuraminidase (NA) are the primary surface glycoproteins of the highly pathogenic avian influenza virus. HA mediates viral entry by binding to alpha-2,3-linked sialic acid receptors on host cells and facilitating membrane fusion within endosomes (Source: UniProt P03466). NA is a glycosyl hydrolase that cleaves terminal sialic acid residues, allowing the release of newly formed virions from the infected cell surface and preventing viral aggregation (Source: UniProt P03472). These proteins are the principal targets for the host immune response, and their specific epitopes are the focus of vaccine development and monoclonal antibody therapy. Therapeutic agents like oseltamivir and zanamivir specifically target the enzymatic active site of NA to inhibit viral spread. Because H5N1 poses a significant pandemic threat with high mortality rates in humans, these epitopes are critical for global surveillance and the design of pre-pandemic countermeasures (Source: WHO, CDC). Monitoring mutations in these epitopes is essential to address emerging drug resistance and ensure the efficacy of seasonal and pandemic vaccines.

Other names

H5N1 surface glycoproteinsH5 HAN1 NAAvian influenza antigensHemagglutinin-neuraminidase complex

Neuraminidase inhibitors (e.g., oseltamivir) competitively bind to the active site of the NA enzyme, preventing the cleavage of sialic acid and thereby trapping progeny virions at the host cell surface (Source: PubChem, CID 65028). Hemagglutinin-targeted interventions, such as vaccines and neutralizing antibodies, bind to specific epitopes on the HA globular head or stem to block viral attachment to host receptors or inhibit the conformational change required for membrane fusion (Source: PubMed, PMID 22722287).